Literature DB >> 7806370

Expression and purification of Shiga-like toxin II B subunits.

D W Acheson1, S A De Breucker, M Jacewicz, L L Lincicome, A Donohue-Rolfe, A V Kane, G T Keusch.   

Abstract

Shiga-like toxins (SLTs), which are produced by certain strains of Escherichia coli, are composed of enzymatically active A and B subunit multimers responsible for the toxin's binding. We have previously purified large amounts of the SLT-I B subunit by using a hyperexpression vector in Vibrio cholerae under the control of the trc promoter. In this study we examined various expression vectors to maximize yields of the SLT-II B subunit. The SLT-II B subunit has been expressed by using both the T7 promoter and the tac promoter in E. coli. When expressed from a plasmid containing the structural gene for SLT-II B deleted of the leader sequence, SLT-II B was able to form multimers when cross-linked, although SLT-II B production from this plasmid was unreproducible. SLT-II B expressed in all three systems appeared to form unstable multimers, which did not readily bind to a monoclonal antibody which preferentially recognizes B subunit multimers. SLT-II B expression was not increased by moving any of the plasmids into V. cholerae. Polyclonal antibodies raised to SLT-II B in rabbits recognized B subunit in SLT-II holotoxin yet were poorly neutralizing. SLT-II B was also expressed as a fusion protein with maltose-binding protein and could be cleaved from maltose-binding protein with factor Xa. Although the expression vectors were able to make large amounts of SLT-II B, as determined by Western blotting (immunoblotting), the levels of purified SLT-II B subunit were low compared with those obtained previously for SLT-I B subunit, probably because of instability of the multimeric SLT-II B subunit.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7806370      PMCID: PMC172992          DOI: 10.1128/iai.63.1.301-308.1995

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  20 in total

1.  A system for production and rapid purification of large amounts of the Shiga toxin/Shiga-like toxin I B subunit.

Authors:  S B Calderwood; D W Acheson; M B Goldberg; S A Boyko; A Donohue-Rolfe
Journal:  Infect Immun       Date:  1990-09       Impact factor: 3.441

2.  Characterization of Shiga-like toxin I B subunit purified from overproducing clones of the SLT-I B cistron.

Authors:  K Ramotar; B Boyd; G Tyrrell; J Gariepy; C Lingwood; J Brunton
Journal:  Biochem J       Date:  1990-12-15       Impact factor: 3.857

3.  Comparison of the glycolipid receptor specificities of Shiga-like toxin type II and Shiga-like toxin type II variants.

Authors:  J E Samuel; L P Perera; S Ward; A D O'Brien; V Ginsburg; H C Krivan
Journal:  Infect Immun       Date:  1990-03       Impact factor: 3.441

4.  Purification of Shiga toxin and Shiga-like toxins I and II by receptor analog affinity chromatography with immobilized P1 glycoprotein and production of cross-reactive monoclonal antibodies.

Authors:  A Donohue-Rolfe; D W Acheson; A V Kane; G T Keusch
Journal:  Infect Immun       Date:  1989-12       Impact factor: 3.441

5.  Globotriosyl ceramide is specifically recognized by the Escherichia coli verocytotoxin 2.

Authors:  T Waddell; S Head; M Petric; A Cohen; C Lingwood
Journal:  Biochem Biophys Res Commun       Date:  1988-04-29       Impact factor: 3.575

Review 6.  The complete general secretory pathway in gram-negative bacteria.

Authors:  A P Pugsley
Journal:  Microbiol Rev       Date:  1993-03

7.  Comparison of Shiga-like toxin I B-subunit expression and localization in Escherichia coli and Vibrio cholerae by using trc or iron-regulated promoter systems.

Authors:  D W Acheson; S B Calderwood; S A Boyko; L L Lincicome; A V Kane; A Donohue-Rolfe; G T Keusch
Journal:  Infect Immun       Date:  1993-03       Impact factor: 3.441

8.  Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections.

Authors:  S M Ostroff; P I Tarr; M A Neill; J H Lewis; N Hargrett-Bean; J M Kobayashi
Journal:  J Infect Dis       Date:  1989-12       Impact factor: 5.226

9.  Crystal structure of the cell-binding B oligomer of verotoxin-1 from E. coli.

Authors:  P E Stein; A Boodhoo; G J Tyrrell; J L Brunton; R J Read
Journal:  Nature       Date:  1992-02-20       Impact factor: 49.962

10.  Pathogenesis of Shigella diarrhea. IX. Simplified high yield purification of Shigella toxin and characterization of subunit composition and function by the use of subunit-specific monoclonal and polyclonal antibodies.

Authors:  A Donohue-Rolfe; G T Keusch; C Edson; D Thorley-Lawson; M Jacewicz
Journal:  J Exp Med       Date:  1984-12-01       Impact factor: 14.307

View more
  8 in total

1.  Recombinant Shiga toxin B-subunit-keyhole limpet hemocyanin conjugate vaccine protects mice from Shigatoxemia.

Authors:  Paola Marcato; Thomas P Griener; George L Mulvey; Glen D Armstrong
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

2.  Protective immunity to Shiga-like toxin I following oral immunization with Shiga-like toxin I B-subunit-producing Vibrio cholerae CVD 103-HgR.

Authors:  D W Acheson; M M Levine; J B Kaper; G T Keusch
Journal:  Infect Immun       Date:  1996-01       Impact factor: 3.441

3.  The serine 31 residue of the B subunit of Shiga toxin 2 is essential for secretion in enterohemorrhagic Escherichia coli.

Authors:  Takeshi Shimizu; Satomi Kawakami; Toshio Sato; Terumi Sasaki; Masato Higashide; Takashi Hamabata; Toshiko Ohta; Masatoshi Noda
Journal:  Infect Immun       Date:  2007-02-26       Impact factor: 3.441

4.  A DNA vaccine encoding the enterohemorragic Escherichia coli Shiga-like toxin 2 A2 and B subunits confers protective immunity to Shiga toxin challenge in the murine model.

Authors:  Leticia V Bentancor; Marcos Bilen; Romina J Fernández Brando; María Victoria Ramos; Luis C S Ferreira; Pablo D Ghiringhelli; Marina S Palermo
Journal:  Clin Vaccine Immunol       Date:  2009-01-28

5.  Enhanced Actin Pedestal Formation by Enterohemorrhagic Escherichia coli O157:H7 Adapted to the Mammalian Host.

Authors:  Michael John Brady; Padhma Radhakrishnan; Hui Liu; Loranne Magoun; Kenan C Murphy; Jean Mukherjee; Arthur Donohue-Rolfe; Saul Tzipori; John M Leong
Journal:  Front Microbiol       Date:  2011-11-15       Impact factor: 5.640

6.  Novel fusion antigen displayed-bacterial ghosts vaccine candidate against infection of Escherichia coli O157:H7.

Authors:  Kun Cai; Wei Tu; Yuenan Liu; Tao Li; Hui Wang
Journal:  Sci Rep       Date:  2015-12-02       Impact factor: 4.379

7.  Antibodies anti-Shiga toxin 2 B subunit from chicken egg yolk: isolation, purification and neutralization efficacy.

Authors:  Y R Parma; P A Chacana; A Rogé; A Kahl; A Cangelosi; P Geoghegan; P M A Lucchesi; M E Fernández-Miyakawa
Journal:  Toxicon       Date:  2011-07-22       Impact factor: 3.033

8.  Development of DNA vaccines against hemolytic-uremic syndrome in a murine model.

Authors:  Alejandra V E Capozzo; Virginia Pistone Creydt; Graciela Dran; Gabriela Fernández; Sonia Gómez; Leticia V Bentancor; Carolina Rubel; Cristina Ibarra; Martín Isturiz; Marina S Palermo
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.